{
  "docId": "019de071-f36b-702d-acba-b009d415a6aa",
  "docSlug": "7f10ea97b4031d406788e9f98a2cb8e4",
  "documentTitle": "Alkermes | Investor Conference Presentation Deck | 36 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 36,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 7,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f36b-702d-acba-b009d415a6aa/21",
  "deckHref": "/decks/019de071-f36b-702d-acba-b009d415a6aa",
  "deckJsonHref": "/decks/019de071-f36b-702d-acba-b009d415a6aa.json",
  "deckAnchorHref": "/decks/019de071-f36b-702d-acba-b009d415a6aa#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.54,
        "x": 0.06,
        "y": 0.225
      },
      "kind": "chart",
      "text": "VUMERITY Royalty & Manufacturing Revenue ($M)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9fef8037-a0cc-42f3-addd-bd8d9486cc01",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.35,
        "x": 0.63,
        "y": 0.24
      },
      "kind": "list",
      "text": "Novel oral fumarate for the treatment of relapsing forms of multiple sclerosis (MS)\nApproved in U.S. Q4 2019\nBiogen holds exclusive, worldwide license to commercialize\n15% royalty to Alkermes on worldwide net sales\n~$7B oral U.S. MS market*\nMultiple recent regulatory approvals in Europe",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c9f3479-04e7-4288-9447-812a7836c62d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.64,
        "y": 0.895
      },
      "kind": "source-note",
      "text": "*IQVIA NPA data as of Nov 2021 TTM (trailing 12 month)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac169ee7-b3ca-4af3-b4ef-b9c9bc57619b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "VUMERITY® Offers Long-Term Revenue Growth Opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5df307db-a65d-4163-9b3e-e0d65476b8f3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "1c9eb278-7525-48d6-bfaf-4eb2a81f0575",
      "evidence": "chart/bar-vertical: VUMERITY Royalty & Manufacturing Revenue ($M)",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}